

pending applications for renewal of that registration pursuant to 21 U.S.C. 823(f). As a basis for revocation, the Order to Show Cause alleged that Dr. Clement is not currently authorized to practice medicine or handle controlled substances in the State of Louisiana, the state in which he practices. The order also notified Dr. Clement that should no request for a hearing be filed within 30 days, his hearing right would be deemed waived.

The Order to Show Cause was sent by certified mail to Dr. Clement at his registered location in Lake Charles, Louisiana. DEA subsequently received a signed receipt notification indicating that the Order to Show Cause was received on behalf of Dr. Clement on November 29, 2002. DEA has not received a request for hearing or any other reply from Dr. Clement or anyone purporting to represent him in this matter. Therefore, the Deputy Administrator, finding that (1) 30 days have passed since the receipt of the Order to Show Cause, and (2) no request for a hearing having been received, concludes that Dr. Clement is deemed to have waived his hearing right. After considering material from the investigative file in this matter, the Deputy Administrator now enters his final order without a hearing pursuant to 21 CFR 1301.43(d) and (e) and 1301.46.

The Deputy Administrator finds that Dr. Clement currently possesses DEA Certificate of Registration AC3534814 and that registration remains valid until August 31, 2004. The Deputy Administrator further finds that by Opinion and Ruling dated July 31, 2002, the Louisiana State Board of Medical Examiners (Board) ordered the indefinite suspension of Dr. Clement's medical license. The suspension order arose out of Dr. Clement's refusal to undergo inpatient evaluation to ascertain whether he suffered from "a psychiatric, neurologic (sic) or physical condition which render[ed] him incapable of practicing medicine with reasonable skill and safety to patients."

The investigative file contains no evidence that the Board's suspension order has been stayed or that Dr. Clement's medical license has been reinstated. Therefore, the Deputy Administrator finds that Dr. Clement is not currently authorized to practice medicine in the State of Louisiana. As a result, it is reasonable to infer that he is also without authorization to handle controlled substances in that state.

DEA does not have statutory authority under the Controlled Substances Act to issue or maintain a registration if the applicant or registrant is without state

authority to handle controlled substances in the state in the state in which he conducts business. See 21 U.S.C. 802(21), 823(f) and 824(a)(3). This prerequisite has been consistently upheld. See Ramona K. Morris, M.D., 67 FR 68687 (2002); Dominick A. Ricci, M.D., 58 FR 51104 (1993); Bobby Watts, M.D., 53 FR 11919 (1988).

Here, it is clear that Dr. Clement's medical license has been indefinitely suspended, and as a result, he is not licensed to handle controlled substances in the State of Louisiana where he is registered with DEA. Therefore, he is not entitled to a DEA registration in that state.

Accordingly, the Deputy Administrator of the Drug Enforcement Administration, pursuant to the authority vested in him by 21 U.S.C. 823 and 824 and 28 CFR 0.100(b) and 0.104, hereby orders that DEA Certificate of Registration AC3534814, issued to Richard J. Clement, M.D. be, and it hereby is, revoked. The Deputy Administrator further orders that any pending applications for renewal or modification of such registration be, and they hereby are, denied. This order is effective April 14, 2003.

Dated: February 27, 2003.

**John B. Brown III,**

*Deputy Administrator.*

[FR Doc. 03-6102 Filed 3-12-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances Notice of Registration**

By Notice dated July 9, 2002, and published in the **Federal Register** on August 6, 2002, (67 FR 50899), Penick Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Codeine (9050) .....	II
Dihydrocodeine (9120) ....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) ...	II
Hydrocodone (9193) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Oxymorphone (9652) .....	II

The firm plans to bulk manufacture the listed controlled substances for the

manufacture of bulk pharmaceutical controlled substances.

No comments or objections have been received. DEA has considered the factors in Title 21, U.S. section 823(a) and determined that the registration of Penick Corporation to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Penick Corporation to ensure that the company's registration is consistent with the public interest. This investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistance Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: February 28, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-6064 Filed 3-12-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By notice dated June 14, 2002, and published in the **Federal Register** on June 28, 2002, (67 FR 43684), Sigma Aldrich Research Biochemicals, Inc., Attn: Richard Milius, 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
Aminorex (1585) .....	I
Alpha-Ethyltryptamine (7249) .....	I
Lysergic acid diethylamide (7315) .....	I
Tetrahydrocannabinols (7370) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7392) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I

Drug	Schedule
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I
3,4-Methylenedioxyamphetamine (7405).	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I
Heroin (9200)	I
Normorphine (9313)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Nabilone (7379)	II
Phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	II
Cocaine (9041)	II
Codeine (9050)	II
Diprenorphine (9058)	II
Benzoylecgonine (9180)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Meperidine (9230)	II
Metazocine (9240)	II
Methadone (9250)	II
Morphine (9300)	II
Thebaine (9333)	II
Carfentanil (9743)	II
Levo-alphaacetylmethadol (LAAM) (9648).	II
Fentanyl (9801)	II

The firm plans to manufacture the listed controlled substances for laboratory reference standards and neurochemicals.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research Biochemicals, Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: February 28, 2003.  
**Laura M. Nagel,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*  
 [FR Doc. 03-6065 Filed 3-12-03; 8:45 am]  
**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Douglas W. Wooldridge, M.D.;  
 Revocation of Registration**

On March 18, 2002, the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Douglas W. Wooldridge, M.D. (Dr. Wooldridge) of Wellesley Hills, Massachusetts, notifying him of an opportunity to show cause as to why DEA should not revoke his DEA Certificate of Registration, AW1232088 under 21 U.S.C. 824(a), and deny any pending applications for renewal of that registration pursuant to 21 U.S.C. 823(f). As a basis for revocation, the Order to Show Cause alleged that Dr. Wooldridge is not currently authorized to practice medicine or handle controlled substances in the Commonwealth of Massachusetts, the state in which he practices. The order also notified Dr. Wooldridge that should no request for a hearing be filed within 30 days, his hearing right would be deemed waived.

The Order to Show Cause was sent by certified mail to Dr. Wooldridge at his registered location in Wellesley Hills, Massachusetts. On June 6, 2002, DEA received a signed receipt notification indicating that the Order to Show Cause was apparently forwarded from Dr. Wooldridge's registered location to a second location where it was received by a John Wooldridge on March 27, 2002. DEA has not received a request for hearing or any other reply from Dr. Wooldridge or anyone purporting to represent him in this matter. Therefore, the Deputy Administrator, finding that (1) 30 days have passed since the receipt of the Order to Show Cause, and (2) no request for a hearing having been received, concludes that Dr. Wooldridge is deemed to have waived his hearing right. After considering material from the investigative file in this matter, the Deputy Administrator now enters his final order without a hearing pursuant to 21 CFR 1301.43(d) and (e) and 1301.46.

The Deputy Administrator finds that Dr. Wooldridge currently possesses DEA Certificate of Registration AW1232088

and that registration remains valid until May 31, 2003. The Deputy Administration further finds that by Order dated June 13, 2001, the Massachusetts Board of Registration in Medicine (Board) ordered the suspension of Dr. Wooldridge's medical license. The suspension order arose out of Dr. Wooldridge's apparent failure to comply with terms of a probation agreement that he entered into with the Board on March 3, 1999.

The investigative file contains no evidence that the Board's suspension order has been stayed or that Dr. Wooldridge's medical license has been reinstated. Therefore, the Deputy Administrator finds that Dr. Wooldridge is not currently authorized to practice medicine in the Commonwealth of Massachusetts. As a result, it is reasonable to infer that he is also without authorization to handle controlled substances in Massachusetts.

DEA does not have statutory authority under the Controlled Substances Act to issue or maintain a registration if the applicant or registrant is without state authority to handle controlled substances in the state in which he conducts business. See 21 U.S.C. 802(21), 823(f) and 824(a)(3). This prerequisite has been consistently upheld. See *Muttaiya Darमारajeh, M.D.*, 66 FR 52936 (2001); *Dominick A. Ricci, M.D.*, 58 FR 51104 (1993); *Bobby Watts, M.D.*, 53 FR 11919 (1988).

Here, it is clear that Dr. Wooldridge's medical license has been suspended, and as a result, he is not licensed to handle controlled substances in the Commonwealth of Massachusetts where he is registered with DEA. Therefore, he is not entitled to a DEA registration in that state.

Accordingly, the Deputy Administrator of the Drug Enforcement Administration, pursuant to the authority vested in him by 21 U.S.C. 823 and 824 and 28 CFR 0.100(b) and 0.104, hereby orders that DEA Certificate of Registration AW1232088, issued to Douglas W. Wooldridge, M.D. be, and it hereby is, revoked. The Deputy Administrator further orders that any pending applications for renewal of such registration be, and they hereby are, denied. This order is effective April 14, 2003.

Dated: February 27, 2003.  
**John B. Brown III,**  
*Deputy Administrator.*  
 [FR Doc. 03-6101 Filed 3-12-03; 8:45 am]  
**BILLING CODE 4410-09-M**